Hypoglycaemia in adults with insulin-treated diabetes in the UK: self-reported frequency and effects

Diabetic Medicine

Volumn 33, Issue 8, 2016, Pages 1125-1132

  Frier, B M ^a   Jensen, M M ^b   Chubb, B D ^c  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b NOVO NORDISK A S   (Denmark)

^c Novo Nordisk Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN;

ABSENTEEISM; ADULT; ALERTNESS; ARTICLE; DIABETIC PATIENT; DISEASE DURATION; EMPLOYMENT; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH CARE PERSONNEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRODUCTIVITY; QUESTIONNAIRE; SELF REPORT; TREATMENT DURATION; UNITED KINGDOM; WELLBEING;

EID: 84978849186     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12878     Document Type: Article

References (29)

1. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007; 50: 1140–1147.
2. Wild D, von Maltzahn R, Brohan E, Christensen T, Clauson P, Gonder-Frederick L. A critical review of the literature on fear of hypoglycemia in diabetes: implications for diabetes management and patient education. Patient Educ Couns 2007; 68: 10–15.
3. Leiter LA, Yale JF, Chiasson JL, Harris S, Kleinstiver P, Sauriol L. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management. Can J Diabetes 2005; 29: 1–7.
4. Barendse S, Singh H, Frier BM, Speight J. The impact of hypoglycaemia on quality of life and related patient-reported outcomes in type 2 diabetes: a narrative review. Diabet Med 2012; 29: 293–302.
5. Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical investigation of medical products in the treatment or prevention of diabetes mellitus. 2012. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129256.pdf Last accessed 1 March 2015.
6. American Diabetes Association(ADA) Workgroup on Hypoglycemia. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005; 28: 1245–1249.
7. Davis RE, Morrissey M, Peters JR, Wittrup-Jensen K, Kennedy-Martin T, Currie CJ. Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes. Curr Med Res Opin 2005; 21: 1477–1483.
8. Donnelly LA, Morris AD, Frier BM, Ellis JD, Donnan PT, Durrant R et al. Frequency and predictors of hypoglycaemia in type 1 and insulin-treated type 2 diabetes: a population-based study. Diabet Med 2005; 22: 749–755.
9. Pramming S, Thorsteinsson B, Bendtson I, Binder C. Symptomatic hypoglycaemia in 411 type 1 diabetic patients. Diabet Med 1991; 8: 217–222.
10. Chico A, Vidal-Rios P, Subira M, Novials A. The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes Care 2003; 26: 1153–1157.
11. Choudhary P, Geddes J, Freeman JV, Emery CJ, Heller SR, Frier BM. Frequency of biochemical hypoglycaemia in adults with type 1 diabetes with and without impaired awareness of hypoglycaemia: no identifiable differences using continuous glucose monitoring. Diabet Med 2010; 27: 666–672.
12. Lundkvist J, Berne C, Bolinder B, Jonsson L. The economic and quality of life impact of hypoglycemia. Eur J Health Econ 2005; 6: 197–202.
13. Östenson CG, Geelhoed-Duijvestijn P, Lahtela J, Weitgasser R, Markert Jensen M, Pedersen-Bjergaard U. Self-reported non-severe hypoglycaemic events in Europe. Diabet Med 2014; 31: 92–101.
14. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al. Management of hyperglycaemia in type 2 diabetes: a patient-centred approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577–1596.
15. Pedersen-Bjergaard U, Pramming S, Heller SR, Wallace TM, Rasmussen AK, Jorgensen HV et al. Severe hypoglycemia in 1076 adult patients with type 1 diabetes: influence of risk markers and selection. Diabetes Metab Res Rev 2004; 20: 479–486.
16. Frier BM, Heller SR. Epidemiology and impact of hypoglycemia on patients with diabetes. Maryland: The Endocrine Society, 2012. Available at http://www.endocrine.org/~/media/endosociety/Files/EP/Hyperglycemia.pdf. Last accessed 20 March 2015.
17. Brod M, Wolden M, Christensen T, Bushnell DM. A nine country study of the burden of non-severe nocturnal hypoglycaemic events on diabetes management and daily function. Diabetes Obes Metab 2013; 15: 546–557.
18. Geelhoed-Duijvestijn PH, Pedersen-Bjergaard U, Weitgasser R, Lahtela J, Jensen MM, Östenson CG. Effects of patient-reported non-severe hypoglycemia on healthcare resource use, work-time loss, and wellbeing in insulin-treated patients with diabetes lin seven European countries. J Med Econ 2013; 16: 1453–1461.
19. Brod M, Christensen T, Thomsen TL, Bushnell DM. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health 2011; 14: 665–671.
20. Brod M, Pohlman B, Wolden M, Christensen T. Non-severe nocturnal hypoglycemic events: experience and impacts on patient functioning and well-being. Qual Life Res 2013; 22: 997–1004.
21. European Society for Opinion and Marketing Research (ESOMAR). ICC/ESOMAR international code on market and social research. 2007. Available at http://www.esomar.org/uploads/public/knowledge-and-standards/codes-and-guidelines/ESOMAR_ICC-ESOMAR_Code_English.pdf Last accessed 1 March 2015.
22. European Pharmaceutical Market Research Association (EphMRA). Code of conduct. 1997. Available at http://www.ephmra.org/code-of-conduct/2/A-Purpose-Scope-and-Sources Last accessed 1 March 2015.
23. Kristensen PL, Hansen LS, Jespersen MJ, Pedersen-Bjergaard U, Beck-Nielsen H, Christiansen JS et al. Insulin analogues and severe hypoglycaemia in type 1 diabetes. Diabetes Res Clin Pract 2012; 96: 17–23.
24. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357: 1716–1730.
25. Gale EA, Tattersall RB. Unrecognised nocturnal hypoglycaemia in insulin-treated diabetics. Lancet 1979; 1: 1049–1052.
26. Matyka KA, Wigg L, Pramming S, Stores G, Dunger DB. Cognitive function and mood after profound nocturnal hypoglycaemia in prepubertal children with conventional insulin treatment for diabetes. Arch Dis Child 1999; 81: 138–142.
27. Cheyne E, Kerr D. Making ‘sense’ of diabetes: using a continuous glucose sensor in clinical practice. Diabetes Metab Res Rev 2002; 18(Suppl 1): S43–S48.
28. Pedersen-Bjergaard U, Færch L, Thorsteinsson B. Implementation of new EU driver's license legislation may hamper reporting of severe hypoglycemia by patients with type 1 diabetes. Diabetes 2014; 63: A103–A170.
29. Internet World Stats. Usage and population statistics. 2014. Available at http://www.internetworldstats.com/europa.htm#uk Last accessed 1 March 2015.